Overview Dividends

(EW) Edwards Lifesciences - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US28176E1082

Valve, Replacement, Repair, Surgical

Health Care Equipment
Market Cap in USD: 50,990m
IPO / Inception: 2000-03-27
Return 12m vs S&P 500: -1.74%

EPS (Earnings per Share)

EPS (Earnings per Share) of EW over the last years for every Quarter: "2020-12": 0.5, "2021-03": 0.54, "2021-06": 0.64, "2021-09": 0.54, "2021-12": 0.51, "2022-03": 0.6, "2022-06": 0.63, "2022-09": 0.61, "2022-12": 0.64, "2023-03": 0.62, "2023-06": 0.66, "2023-09": 0.59, "2023-12": 0.64, "2024-03": 0.66, "2024-06": 0.7, "2024-09": 0.67, "2024-12": 0.59, "2025-03": 0.64, "2025-06": 0.67, "2025-09": 0.67, "2025-12": 0,
EPS CAGR: -46.41%
EPS Trend: -33.8%
Last SUE: -4.00
Qual. Beats: 0

Revenue

Revenue of EW over the last years for every Quarter: 2020-12: 1191.7, 2021-03: 1216.6, 2021-06: 1376, 2021-09: 1310.2, 2021-12: 1329.7, 2022-03: 1341.2, 2022-06: 1373.9, 2022-09: 1319, 2022-12: 1348.3, 2023-03: 1459.6, 2023-06: 1295.5, 2023-09: 1243.4, 2023-12: 1266.4, 2024-03: 1329.9, 2024-06: 1385.9, 2024-09: 1354.4, 2024-12: 1385.8, 2025-03: 1412.7, 2025-06: 1532.2, 2025-09: 1553.1, 2025-12: null,
Rev. CAGR: 4.23%
Rev. Trend: 53.4%
Last SUE: 0.31
Qual. Beats: 0

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 26.6%
Value at Risk 5%th 37.1%
Relative Tail Risk -15.41%
Reward TTM
Sharpe Ratio 0.49
Alpha 3.42
CAGR/Max DD 0.11
Character TTM
Hurst Exponent 0.433
Beta 0.520
Beta Downside 0.526
Drawdowns 3y
Max DD 37.53%
Mean DD 16.41%
Median DD 18.69%

Description: EW Edwards Lifesciences December 04, 2025

Edwards Lifesciences Corp (NYSE:EW) designs, manufactures, and sells medical devices that treat advanced cardiovascular disease, focusing on transcatheter heart valve replacement (TAVR) and repair solutions for aortic, mitral, and tricuspid valves. Its flagship SAPIEN platform dominates minimally invasive aortic valve replacement, while the PASCAL PRECISION and Cardioband families address mitral and tricuspid pathologies. The firm also offers surgical structural-heart products under the INSPIRIS brand, leveraging RESILIA tissue and VFit technology to extend valve durability.

Key recent data points: • FY 2023 revenue reached approximately $5.1 billion, with a 12% YoY increase driven largely by TAVR sales. • The SAPIEN platform captured roughly 70% of the U.S. TAVR market, a segment projected to grow at a 9% CAGR through 2029. • Edwards’ operating margin expanded to 22% in Q4 2023, reflecting higher pricing power amid favorable Medicare reimbursement trends for transcatheter procedures.

For a deeper quantitative dive, you might explore ValueRay’s analyst dashboard, which aggregates recent earnings estimates and valuation metrics for EW.

Piotroski VR‑10 (Strict, 0-10) 6.5

Net Income (1.36b TTM) > 0 and > 6% of Revenue (6% = 353.0m TTM)
FCFTA 0.09 (>2.0%) and ΔFCFTA 5.21pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 81.09% (prev 89.64%; Δ -8.55pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.11 (>3.0%) and CFO 1.42b > Net Income 1.36b (YES >=105%, WARN >=100%)
Net Debt (-1.99b) to EBITDA (1.74b) ratio: -1.14 <= 3.0 (WARN <= 3.5)
Current Ratio 4.00 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (585.7m) change vs 12m ago -2.07% (target <= -2.0% for YES)
Gross Margin 78.22% (prev 79.37%; Δ -1.15pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 44.84% (prev 41.14%; Δ 3.70pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 80.08 (EBITDA TTM 1.74b / Interest Expense TTM 19.8m) >= 6 (WARN >= 3)

Altman Z'' 11.63

(A) 0.36 = (Total Current Assets 6.36b - Total Current Liabilities 1.59b) / Total Assets 13.27b
(B) 1.07 = Retained Earnings (Balance) 14.15b / Total Assets 13.27b
warn (B) unusual magnitude: 1.07 — check mapping/units
(C) 0.12 = EBIT TTM 1.59b / Avg Total Assets 13.12b
(D) 4.75 = Book Value of Equity 14.56b / Total Liabilities 3.07b
Total Rating: 11.63 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 71.83

1. Piotroski 6.50pt
2. FCF Yield 2.46%
3. FCF Margin 20.50%
4. Debt/Equity 0.07
5. Debt/Ebitda -1.14
6. ROIC - WACC (= 4.44)%
7. RoE 13.35%
8. Rev. Trend 53.39%
9. EPS Trend -33.82%

What is the price of EW shares?

As of January 01, 2026, the stock is trading at USD 86.20 with a total of 1,340,108 shares traded.
Over the past week, the price has changed by -0.03%, over one month by +1.09%, over three months by +11.67% and over the past year by +16.11%.

Is EW a buy, sell or hold?

Edwards Lifesciences has received a consensus analysts rating of 3.69. Therefor, it is recommend to hold EW.
  • Strong Buy: 10
  • Buy: 4
  • Hold: 17
  • Sell: 0
  • Strong Sell: 1

What are the forecasts/targets for the EW price?

Issuer Target Up/Down from current
Wallstreet Target Price 95.8 11.1%
Analysts Target Price 95.8 11.1%
ValueRay Target Price 92.8 7.6%

EW Fundamental Data Overview December 28, 2025

Market Cap USD = 50.99b (50.99b USD * 1.0 USD.USD)
P/E Trailing = 38.0921
P/E Forward = 30.3951
P/S = 8.6661
P/B = 4.9068
P/EG = 4.8614
Beta = 0.967
Revenue TTM = 5.88b USD
EBIT TTM = 1.59b USD
EBITDA TTM = 1.74b USD
Long Term Debt = 598.2m USD (from longTermDebt, last quarter)
Short Term Debt = 26.8m USD (from shortTermDebt, last quarter)
Debt = 700.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -1.99b USD (from netDebt column, last quarter)
Enterprise Value = 49.00b USD (50.99b + Debt 700.3m - CCE 2.69b)
Interest Coverage Ratio = 80.08 (Ebit TTM 1.59b / Interest Expense TTM 19.8m)
FCF Yield = 2.46% (FCF TTM 1.21b / Enterprise Value 49.00b)
FCF Margin = 20.50% (FCF TTM 1.21b / Revenue TTM 5.88b)
Net Margin = 23.19% (Net Income TTM 1.36b / Revenue TTM 5.88b)
Gross Margin = 78.22% ((Revenue TTM 5.88b - Cost of Revenue TTM 1.28b) / Revenue TTM)
Gross Margin QoQ = 77.77% (prev 77.64%)
Tobins Q-Ratio = 3.69 (Enterprise Value 49.00b / Total Assets 13.27b)
Interest Expense / Debt = 2.83% (Interest Expense 19.8m / Debt 700.3m)
Taxrate = 16.10% (56.1m / 348.4m)
NOPAT = 1.33b (EBIT 1.59b * (1 - 16.10%))
Current Ratio = 4.00 (Total Current Assets 6.36b / Total Current Liabilities 1.59b)
Debt / Equity = 0.07 (Debt 700.3m / totalStockholderEquity, last quarter 10.21b)
Debt / EBITDA = -1.14 (Net Debt -1.99b / EBITDA 1.74b)
Debt / FCF = -1.65 (Net Debt -1.99b / FCF TTM 1.21b)
Total Stockholder Equity = 10.22b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.28% (Net Income 1.36b / Total Assets 13.27b)
RoE = 13.35% (Net Income TTM 1.36b / Total Stockholder Equity 10.22b)
RoCE = 14.66% (EBIT 1.59b / Capital Employed (Equity 10.22b + L.T.Debt 598.2m))
RoIC = 12.30% (NOPAT 1.33b / Invested Capital 10.82b)
WACC = 7.85% (E(50.99b)/V(51.69b) * Re(7.93%) + D(700.3m)/V(51.69b) * Rd(2.83%) * (1-Tc(0.16)))
Discount Rate = 7.93% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -1.76%
[DCF Debug] Terminal Value 73.79% ; FCFE base≈924.4m ; Y1≈709.8m ; Y5≈444.0m
Fair Price DCF = 14.36 (DCF Value 8.33b / Shares Outstanding 580.3m; 5y FCF grow -27.59% → 3.0% )
EPS Correlation: -33.82 | EPS CAGR: -46.41% | SUE: -4.0 | # QB: 0
Revenue Correlation: 53.39 | Revenue CAGR: 4.23% | SUE: 0.31 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.68 | Chg30d=-0.001 | Revisions Net=-2 | Analysts=23
EPS next Year (2026-12-31): EPS=2.87 | Chg30d=+0.007 | Revisions Net=+6 | Growth EPS=+11.1% | Growth Revenue=+9.7%

Additional Sources for EW Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle